替罗非班
医学
改良兰金量表
冲程(发动机)
安慰剂
脑出血
随机对照试验
临床终点
闭塞
临床试验
内科学
外科
经皮冠状动脉介入治疗
心肌梗塞
蛛网膜下腔出血
缺血性中风
缺血
替代医学
病理
工程类
机械工程
作者
Zhongming Qiu,Fengli Li,Hongfei Sang,Wenhua Liu,Wenguo Huang,Huagang Li,Min Zhang,Peiyang Zhou,Bo Lei,Zhiming Zhou,Jeffrey L. Saver,Raul G Nogueira,Wenjie Zi,Qingwu Yang
标识
DOI:10.1177/17474930211069510
摘要
Background: Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, has been shown to reduce the risk of thrombotic complications during percutaneous coronary intervention. However, it remains unknown whether tirofiban improves outcomes in large vessel occlusion stroke patients undergoing endovascular treatment. Objective: This trial aims to assess whether additional intravenous tirofiban therapy can improve the clinical outcomes in large vessel occlusion stroke patients who undergo endovascular treatment within 24 h of symptom onset. Methods and design: The Endovascular Treatment With versus Without Tirofiban for Stroke Patients With Large Vessel Occlusion (RESCUE BT) Trial is an investigator-initiated, randomized, placebo-controlled, double-blind, multicenter trial. Up to 930 eligible patients will be consecutively randomized to intravenous tirofiban or placebo in 1:1 ratio over 3 years across 50 endovascular-capable stroke centers in China. Outcomes: The primary end point is the disability level as measured by overall distribution of the 90-day modified Rankin Scale scores. Primary safety end points include symptomatic intracerebral hemorrhage at 48 h and mortality at 90 days. Trial registry number: ChiCTR-INR-17014167 ( www.chictr.org.cn ).
科研通智能强力驱动
Strongly Powered by AbleSci AI